Dianthus Therapeutics, Inc.
DNTH
Positions held
Your positionsDNTH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Dianthus Therapeutics operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and high returns for investors as innovative treatments gain regulatory approval.
- Revenue increased by 64% compared to the prior quarter, reaching $0.8 million.
- The company has a strong recommendation of 'strong_buy' with a target mean price of $140.8.
- The company is currently facing significant operational challenges, reflected in its negative profit margins and high operating losses, which could deter investors.
- Operating margin remains extremely negative at -8079.1%.
- The overall score indicates a 'Strong Sell' with a score of -16.00, highlighting bearish trends in key indicators.
Fundamentals
| Market cap | $4.61B | Enterprise value | $3.73B | Trailing P/E | — | Forward P/E | -17.88 |
| PEG | — | Price / book | 3.85 | Beta | 0.18 | Dividend yield | 0.00% |
| Revenue growth | 2.9% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -80.8% |
| Profit margin | 0.0% | ROE | -26.1% | ROA | -17.7% | Debt / equity | 0.00 |
| Current ratio | 26.10 | Free cash flow | -$92.21M | Analyst recommendation | strong_buy | Mean target | $140.80 |
| 52w high | $117.88 | 52w low | $32.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.8M | $0.5M | $0.3M | $0.4M | $0.2M |
| Op margin | -8079.1% | -10050.3% | -24486.3% | -10173.7% | -18096.9% |
| Net income | -$50.2M | -$40.8M | -$64.4M | -$36.8M | -$31.6M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$61.5M | -$46.5M | -$69.5M | -$40.3M | -$34.9M |
- Revenue +64% vs prior quarter ($0.8M vs $0.5M).
- Operating margin expanded to -8079.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | $6.4M |
| Op margin | -8739.3% | -1633.7% | -1704.7% | -462.9% |
| Net income | -$162M | -$85.0M | -$43.6M | -$28.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$178M | -$102M | -$48.2M | -$29.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Top Bank Names 6 Stocks With Major Catalysts Ahead
2026-10-01 · Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 · Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
2026-09-24 · Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
2026-09-24 · Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run
2026-09-11 · JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating
2026-09-05 · Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
2026-09-04 · UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
2026-09-04 · Citigroup Initiates Dianthus Therapeutics at Buy With $156 Price Target
2026-09-02 · Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Dianthus Therapeutics to Participate in Three Investor Conferences During September
2026-08-11 · Dianthus Therapeutics Insider Sold Shares Worth $844,822, According to a Recent SEC Filing
Price (daily)
Full chart · RSI · MACD · patterns